

**Remarks**

Claims 1-94 were pending. By this amendment claim 70 is currently amended, claims 6, 7-11, 18-21, 29-31, 33-35, 37-38, 40-43, 45, 47, 50-65, 68-69, 71-87, and 89-93 are canceled without prejudice or disclaimer, and new claims 95-99 are added. No new subject matter is added. Remaining claims are numbered 1-5, 12-17, 22-28, 32, 36, 39, 44, 46, 48, 49, 66, 67, 70, 88, and 94-99.

Claim 70 is currently amended to recite an oligonucleotide of claim 1, rather than an oligonucleotide of any one of claims 1-69, thereby removing any alleged multiple dependency. This amendment is made solely for the purpose of reducing the filing fee. To remove any possible doubt, Applicant does not intend by the current amendment to claim 70 to signal its abandonment of any scope of original claim 70 and hereby expressly reserves the right to pursue any or all such originally claimed subject matter in this or any continuation application.

Claims 7-11, 29-31, 33-35, 37-38, 40-43, 45, 47, 50-65, 68-69, 71-87, and 89-93 are canceled without prejudice or disclaimer, solely for the purpose of reducing the filing fee. To remove any possible doubt, Applicant does not intend by the cancellation of these claims to signal its abandonment of any scope of such original claims and hereby expressly reserves the right to pursue any or all such originally claimed subject matter in this or any continuation application.

Original claims 6 and 18-21 have been canceled and re-presented as new claims 95-99.

Applicant has submitted a substitute sequence listing as required by the Notice to File Missing Parts. The substitute sequence listing includes the following amendments compared to the sequence listing originally filed with the application. Priority information and current application serial number have been corrected for accuracy. SEQ ID NOs: 18, 19, 20, and 57 have been amended to add the maximum number of n residues and to recite the phrase "wherein any of one to seven n may be absent" or "wherein any of one to twenty n may be absent" in

identifier <223> for each of these sequences, as appropriate. A typographical error associated with identifier <223> has been corrected for each of SEQ ID NOs 12, 13, 28, 51, and 58, such that "dezaguanine" now reads "deazaguanine". SEQ ID NO:380 has been amended to correct the misc\_feature length from (8)...(20) to (8)...(19). The term "Synthetic" has been added before the term "Oligodeoxynucleotide" in identifier <223> for each sequence, further to identify the source of each sequence as a synthetic oligodeoxynucleotide. No new matter has been added.

Applicant believes the application is in condition for allowance. An early and favorable response is solicited.

Respectfully submitted,  
*Krieg et al., Applicant*



---

By: Alan W. Steele, Reg. No. 45,128  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA, 02210  
Tel. 617.646.8000

Docket No. C1037.70048US00  
Date: November 10, 2004  
**x11/15/04x**